United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine United Therapeutics (Nasdaq: UTHR) reported full Phase 3 TETON-2 results showing nebulized Tyvaso met the primary endpoint in idiopathic pulmonary fibrosis (IPF).At week 52, mean absolute FVC change was −49.9 mL for Tyvaso versus −136.4 mL for placebo (between-group difference 95.6 mL; P<0.001); clinical worsening risk fell 29% (HR 0.71; P=0.02). Study enrolled 597 patients; 75.4% were on background antifibrotic therapy. No new safety signals observed. United Therapeutics plans an sNDA filing in the second half of 2026.

#UTHR United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

www.stocktitan.net/news/UTHR/united-therape...

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program United Therapeutics (Nasdaq: UTHR) authorized a $2.0 billion share repurchase program and entered into $1.5 billion of Accelerated Share Repurchase (ASR) agreements with Citibank, comprising $750 million uncollared and $750 million collared ASRs.The company will make an upfront payment of $1.5 billion on or around March 11, 2026 and receive initial share deliveries (about 70% of uncollared and 50% of collared amounts), with final settlements expected in Q2 and Q3 2026.

#UTHR United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

www.stocktitan.net/news/UTHR/united-therape...

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #YPF 20.6x
2. #UTHR 12.5x
3. #EOSE 4.4x
4. #RUN 3.7x
5. #SPT 3.3x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#LOW, #PARR, #JBS, #BKSY, #UTHR

#OptionFlow #OptionsTrading #Trading

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease United Therapeutics (Nasdaq: UTHR) announced the first transplant in its ongoing EXPAND clinical study of the investigational UKidney xenokidney in patients with end-stage renal disease on November 3, 2025. The operation was performed at NYU Langone Health. The UKidney used in the transplant is from a pig with 10 gene edits: six human genes added to improve immunologic compatibility and four porcine genes knocked out to reduce rejection risk and moderate organ growth.The company described the trial as a first-of-its-kind effort to evaluate xenotransplantation as an alternative to lifelong dialysis, with stated emphasis on patient safety and continued scientific study.

#UTHR United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

www.stocktitan.net/news/UTHR/united-therape...

95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial Tyvaso demonstrated superior 95.6mL FVC improvement vs placebo in IPF treatment trial. Study met primary and key secondary endpoints, showing benefits across all patient subgroups with statistical significance.

#UTHR United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/UTHR/united-therape...

United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move Biotech leader commits $1B to accelerated share repurchase program, split between collared and uncollared agreements. See how this impacts shareholder value.

#UTHR United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

www.stocktitan.net/news/UTHR/united-therape...

Earnings Summary on United Therapeutics | The Motley Fool

#UTHR #13d4ea51-48cd-4cde-8a3d-35ccbf446eb9 #data-news

Origin | Interest | Match

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results United Therapeutics (NASDAQ:UTHR) reported strong Q2 2025 financial results with record total revenue of $798.6 million, up 12% year-over-year, marking 12 consecutive quarters of double-digit growth. The company's Board authorized a $1 billion share repurchase program through March 2026.Key highlights include Tyvaso DPI's record revenue of $315.2 million (22% growth), strong performance from Nebulized Tyvaso, Orenitram, and Unituxin. Net income reached $309.5 million ($6.41 per diluted share). The company expects continued double-digit revenue growth, supported by its commercial portfolio and late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.Important upcoming catalysts include the TETON 2 study results in September 2025 for idiopathic pulmonary fibrosis and ADVANCE OUTCOMES study data in H1 2026 for pulmonary arterial hypertension.

#UTHR United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results

www.stocktitan.net/news/UTHR/united-therape...

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver United Therapeutics (NASDAQ:UTHR) and Intermountain Health have achieved a groundbreaking milestone with the world's first patient treatment using miroliverELAP®, a bioengineered external liver assist product. The procedure was performed at Intermountain Medical Center in Murray, Utah, on a patient with liver failure who wasn't eligible for transplant.MiroliverELAP, developed by UTHR subsidiary Miromatrix Medical, consists of a single-use MIRO-001 bioengineered liver and extracorporeal blood circuit. The technology uses a decellularized porcine liver scaffold combined with human endothelial and liver cells. This Phase 1 study represents the first human clinical trial of a manufactured organ alternative, addressing a critical need as approximately 30% of acute liver failure patients die without access to liver transplants.

#UTHR United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

www.stocktitan.net/news/UTHR/united-therape...

Major Breakthrough: 728-Patient Phase 3 Trial Advances First Once-Daily Oral PAH Treatment Landmark study of ralinepag shows 29.8% PVR reduction in Phase 2. Final Phase 3 data expected H1 2026 could revolutionize PAH treatment. Get insights.

#UTHR United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

www.stocktitan.net/news/UTHR/united-therape...

United Therapeutics Corporation Reports First Quarter 2025 Financial Results United Therapeutics reported strong Q1 2025 financial results with total revenues reaching $794.4 million, marking a 17% increase from Q1 2024. The company's flagship product Tyvaso led growth with total revenues of $466.3 million, up 25% year-over-year. Key highlights include net income of $322.2 million and earnings per diluted share of $6.63. Tyvaso DPI showed exceptional performance with a 33% revenue increase to $302.5 million. The growth was driven by increased patient numbers and Medicare Part D benefit redesign implementation. The company announced progress in their organ transplant alternatives program, with planned FDA applications for UHeart and UThymoKidney products. They also expect results from the TETON 2 trial in idiopathic pulmonary fibrosis and plan to commence UKidney human clinical studies.

#UTHR United Therapeutics Corporation Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/UTHR/united-therape...

How United Therapeutics Drove 24% Revenue Growth in 2024 - Key Products and Pipeline Updates Tyvaso product line led with 31% growth to $1.62B. Pipeline advances include fully enrolled TETON studies and FDA clearance for xenotransplantation trial.

#UTHR United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/UTHR/united-therape...

Breakthrough IPF Treatment Study Hits Key Milestone: 598 Patients Enrolled in Game-Changing Tyvaso Trial United Therapeutics advances Tyvaso IPF program with full enrollment of 598 patients in TETON 1 study, building on promising INCREASE trial results. Data expected H1 2026.

#UTHR United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/UTHR/united-therape...

Revolutionary Pig-to-Human Kidney Transplant Trial Gets Historic FDA Green Light United Therapeutics advances xenotransplantation with FDA clearance for UKidney™ human trials, offering hope to 557,000+ dialysis patients. First transplants planned for 2025.

#UTHR United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

www.stocktitan.net/news/UTHR/united-therape...

United Therapeutics to Present Groundbreaking Tyvaso DPI Data at PVRI 2025 Congress United Therapeutics showcases real-world dosing data and long-term outcomes for Tyvaso DPI, plus interim PHINDER study results at PVRI 2025 Congress in Rio de Janeiro.

#UTHR United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

www.stocktitan.net/news/UTHR/united-therape...

#UTHR announces successful world-first UKidney transplant! Despite regulatory hurdles, the company remains promising with a cautious hold rating maintained by Morgan Stanley.

#HealthcareInnovation #TransplantSuccess

markets.businessinsider.com/news/stocks/...

United Therapeutics Makes History: First-Ever Genetically Modified Pig Kidney Transplant Success Groundbreaking xenotransplant milestone as United Therapeutics successfully performs world's first UKidney™ transplant, featuring 10 gene edits, at NYU Langone Health.

#UTHR United Therapeutics Announces Successful World’s First UKidney Transplant

www.stocktitan.net/news/UTHR/united-therape...

BREAKING NEWS: ( NASDAQ: #UTHR ) Outperform Recommendation Issued On UTHR By Oppenheimer

#StockMarket #News

JUST IN: ( NASDAQ: #UTHR ) United Therapeutics Corporation to Present at Upcoming Investor Conferences

#StockMarket #News